Bayer AG stock closed Thursday at €47.81 and is down -3.2% on a sharp decline before the weekend. A critical point seems to be the ongoing discussion about the total herbicide glyphosate, which Bayer AG would like to extend its approval in the EU for another ten years. Critics such as Rita Triebskorn from the University of Tübingen see such a renewal as “scientifically unfounded and completely inappropriate.”
Meanwhile, the EU Commission is sticking to its proposal, which will be put to a vote on October 13.
Scientific controversy: Bayer AG shares on the firing line
- Bayer AG wants to extend approval of glyphosate
- Critics consider the EU proposal inappropriate
- Global sales of glyphosate-containing products is a billion-dollar market
Sollten Anleger sofort verkaufen? Oder lohnt sich doch der Einstieg bei Bayer AG?
While Bayer AG shares are under scrutiny, the debates about the approval of glyphosate are intensifying. Scientists such as Johann Zaller from the University of Natural Resources and Life Sciences (BOKU) in Vienna accuse the EU of systematically denying the progressive loss of biodiversity. Christoph Schäfers from the Fraunhofer Institute, on the other hand, assesses the proposal as “appropriate” and emphasizes the restriction of the approval to 10 years instead of the usual 15.
Regulatory uncertainty: Bayer AG stock as a high-risk investment?
- Uncertainties in regulation weigh on Bayer AG stock
- Restrictions and conditions imposed by the EU Commission criticized as insufficient
- Experts demand better toxicological and ecotoxicological data
The fluctuating performance of Bayer AG stock may be exacerbated by the uncertainty surrounding the regulation of glyphosate. Although the EU Commission is planning restrictions, these are considered insufficient. Particular criticism is levelled at the insufficient toxicological and ecotoxicological findings used as a reason for extending the approval.
Sollten Anleger sofort verkaufen? Oder lohnt sich doch der Einstieg bei Bayer AG?
The next step: Bayer AG shares face important decision
On October 13, a decisive vote on the renewal of the approval of glyphosate is due, which could have a significant impact on the performance of Bayer AG shares. The agrochemical giant Bayer has already welcomed the draft regulation, while opposition is coming from Germany. A final decision is therefore still open and could either stabilize the share or drive it further down.
Buy, hold, or sell? – Your Bayer AG analysis of 22/09 provides the answer:
What are the prospects for Bayer AG´s development? Is this stock a safe investment for your money?
The answers to these questions and why you need to act now can be found in the current analysis of Bayer AG stock.
Autor
Kaufen, halten oder verkaufen - Ihre Bayer AG-Analyse von 17.11. liefert die Antwort:
Wie wird sich Bayer AG jetzt weiter entwickeln? Ist ihr Geld in dieser Aktie sicher? Die Antworten auf diese Fragen und warum Sie jetzt handeln müssen, erfahren Sie in der aktuellen Analyse zur Bayer AG Aktie
